

# Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma

Sandile Cele<sup>1,2</sup>, Inbal Gazy<sup>2,3,4</sup>, Laurelle Jackson<sup>1</sup>, Shi-Hsia Hwa<sup>1,5</sup>, Houriiyah Tegally<sup>3</sup>, Gila Lustig<sup>6</sup>, Jennifer Giandhari<sup>3</sup>, Sureshnee Pillay<sup>3</sup>, Eduan Wilkinson<sup>3</sup>, Yeshnee Naidoo<sup>3</sup>, Farina Karim<sup>1,2</sup>, Yashica Ganga<sup>1</sup>, Khadija Khan<sup>1</sup>, Alejandro B. Balazs<sup>7</sup>, Bernadett I. Gosnell<sup>8</sup>, Willem Hanekom<sup>1,5</sup>, Mahomed-Yunus S. Moosa<sup>8</sup>, NGS-SA<sup>§</sup>, COMMIT-KZN Team<sup>§§</sup>, Richard J. Lessells<sup>2,3,6</sup>, Tulio de Oliveira<sup>2,3,6,9\*</sup>, Alex Sigal<sup>1,2,10\*</sup>

<sup>1</sup>Africa Health Research Institute, Durban 4001, South Africa. <sup>2</sup>School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban 4001, South Africa. <sup>3</sup>KwaZulu-Natal Research Innovation and Sequencing Platform, Durban 4001, South Africa. <sup>4</sup>Department of Biochemistry and Molecular Biology, The Institute for Medical Research Israel-Canada, Hadassah Medical School, The Hebrew University of Jerusalem, 91120, Jerusalem, Israel. <sup>5</sup>Division of Infection and Immunity, University College London, London WC1E 6BT, UK. <sup>6</sup>Centre for the AIDS Programme of Research in South Africa, Durban 4001, South Africa. <sup>7</sup>Ragon Institute of MGH, Harvard, and MIT, Cambridge, USA. <sup>8</sup>Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban 4001, South Africa. <sup>9</sup>Department of Global Health, University of Washington, Seattle, USA. <sup>10</sup>Max Planck Institute for Infection Biology, Berlin 10117, Germany.

\* Corresponding authors. Email: [deoliveira@ukzn.ac.za](mailto:deoliveira@ukzn.ac.za), [alex.sigal@ahri.org](mailto:alex.sigal@ahri.org)

## 1 Abstract


2 **New SARS-CoV-2 variants with mutations in the spike glycoprotein have arisen inde-**  
3 **pendently at multiple locations and may have functional significance. The combination**  
4 **of mutations in the 501Y.V2 variant first detected in South Africa include the N501Y,**  
5 **K417N, and E484K mutations in the receptor binding domain (RBD) as well as muta-**  
6 **tions in the N-terminal domain (NTD). Here we address whether the 501Y.V2 variant**  
7 **could escape the neutralizing antibody response elicited by natural infection with ear-**  
8 **lier variants. We were the first to outgrow two variants of 501Y.V2 from South Africa,**  
9 **designated 501Y.V2.HV001 and 501Y.V2.HVdF002. We examined the neutralizing ef-**  
10 **fect of convalescent plasma collected from six adults hospitalized with COVID-19 using**  
11 **a microneutralization assay with live (authentic) virus. Whole genome sequencing of the**  
12 **infecting virus of the plasma donors confirmed the absence of the spike mutations which**  
13 **characterize 501Y.V2. We infected with 501Y.V2.HV001 and 501Y.V2.HVdF002 and com-**  
14 **pared plasma neutralization to first wave virus which contained the D614G mutation but**  
15 **no RBD or NTD mutations. We observed that neutralization of the 501Y.V2 variants was**  
16 **strongly attenuated, with  $IC_{50}$  6 to 200-fold higher relative to first wave virus. The de-**  
17 **gree of attenuation varied between participants and included a knockout of neutralization**  
18 **activity. This observation indicates that 501Y.V2 may escape the neutralizing antibody**  
19 **response elicited by prior natural infection. It raises a concern of potential reduced pro-**  
20 **tection against re-infection and by vaccines designed to target the spike protein of earlier**  
21 **SARS-CoV-2 variants.**

22 Through genomic surveillance of the severe acute respiratory syndrome-related coronavirus 2 (SARS-  
23 CoV-2), a number of new variants have recently been identified with multiple mutations in the spike  
24 glycoprotein [1, 2, 3]. We recently described the emergence of the N501Y.V2 variant in South Africa,  
25 characterised by the K417N, E484K, and N501Y mutations in the spike receptor binding domain (RBD)  
26 as well as four substitutions and a deletion in the N-terminal domain (NTD) [1]. This variant was first  
27 detected in October 2020, and has rapidly become the dominant variant in several parts of the country  
28 at a time of a rapid resurgence in infections.

29 The RBD is the main target of neutralizing antibodies (NAbs) elicited by SARS-CoV-2 infection,  
30 with the remaining activity directed at the NTD [4, 5, 6]. All three amino acid residues in the RBD that  
31 carry mutations in 501Y.V2 interact directly with the human angiotensin-converting enzyme 2 (hACE2)  
32 receptor and form part of the epitopes for hACE2-blocking NAbs [7]. The E484 residue specifically is a  
33 hotspot for binding of highly potent NAbs [7]. In a number of separate *in vitro* studies using monoclonal  
34 antibodies (mAbs), mutations at E484 have emerged as immune escape mutations, often conferring broad  
35 cross-resistance to panels of mAbs [8, 9, 10, 11]. E484K also emerged during passage with convalescent  
36 plasma, leading to substantial drops in neutralization with convalescent plasma samples [12, 13]. Using  
37 a deep mutation scanning approach to determine the effect of individual mutations on neutralization by  
38 polyclonal serum, mutations at E484 were associated with the largest drops in neutralization [14].

39 Here, using a microneutralization assay with authentic virus, we address the question of whether  
40 501Y.V2 variants can escape the neutralizing response elicited by natural infection with previous vari-  
41 ants. We outgrew and compared the neutralization of two SARS-CoV-2 501Y.V2 variants to a previously  
42 circulating variant derived from South Africa which does not have the 501Y.V2 defining mutations.

43 For neutralization, we used plasma samples from our ongoing longitudinal cohort study that tracks  
44 COVID-19 cases enrolled at two hospitals in Durban, South Africa [15]. We sampled participants  
45 weekly for the first month post-enrollment, and at each timepoint a blood draw and combined nasopha-  
46 ryngeal/oropharyngeal swab was performed to obtain both the plasma and the infecting virus.



	Outgrown viral variants			Infecting variant sequences of blood plasma donors					
Lineage	B.1.1	501Y.V2 (B.1.351)		B.1.1	B.1.1	B.1.5	B.1.5	B.1.140	B.1.1.1
Sequence ID	K002868	K005321	K005325	K002868	K004289	K004285	K004291	K004295	K004302
Plasma ID	039-13-0013			039-13-0013	039-02-0014	039-13-0015	039-13-0033	039-02-0017	039-13-0062
Isolate designation	CoV2.V003	501Y.V2.HVdF002	501Y.V2.HV001						
Spike mutations	D614G A688V	D80A D215G K417N E484K N501Y D614G A701V	L18F D80A D215G K417N E484K N501Y D614G A701V	D614G A688V	D614G	D614G	D614G	D614G	D614G
Spike indels		242-244del	242-244del						

**Figure 1: Study design and sequences of SARS-CoV-2 variants.** (A) We obtained convalescent plasma and detected the matching infecting variant in the first SARS-CoV-2 infection wave in South Africa. A blood draw and nasopharyngeal/oropharyngeal was performed on study participants. First wave virus was outgrown from one of the participants and compared to two viruses outgrown from the second wave, which were 501Y.V2 variants. A focus forming microneutralization assay was used to quantify neutralization. (B) Phylogenetic tree and mutations of variant sequences. Variants which infected the study participants who were plasma donors only for this study are marked in blue. Sequences of variants which were outgrown are marked in yellow. Participant 039-13-0013 was both a plasma donor and the donor from whom the first wave virus was outgrown. Y-axis denotes time of sampling for viral sequencing. Table shows mutations present in Spike for the 501Y.V2 variants and the first wave virus used in the study. See Table S2 for a complete list of mutations in the viral genomes.


47 We chose plasma from participants from the first infection wave where the infecting virus was suc-  
48 cessfully sequenced (Table S1) and where RBD binding was detected by ELISA. These viruses were  
49 from a variety of B.1 lineages circulating in South Africa and contained the D614G mutation but none  
50 of the spike mutations defining 501Y.V2 (Figure 1, see Table S2 for whole genome mutations). Plasma  
51 samples were from blood drawn approximately 1 month post-symptom onset (Table S1), shown to be  
52 close to the antibody response peak [16, 17].

53 We outgrew first wave virus (Materials and methods) from cohort participant 039-13-0013 during  
54 the first infection wave in South Africa peaking in July 2020, and second wave 501Y.V2 virus from  
55 two samples obtained in the second wave starting November 2020 through our genomic surveillance  
56 program. We used a microneutralization live virus focus forming assay (FFA) [18]. This relies on a  
57 methylcellulose overlay to limit cell-free viral spread, resulting in a local infection focus then detected  
58 by an anti-SARS-CoV-2 Spike antibody (Materials and methods). Re-sequencing of the first 501Y.V2  
59 variant after outgrowth revealed no changes in the RBD or NTD but a deletion in the furin cleavage  
60 site (Table S3) commonly observed after *in vitro* culture in Vero E6 cells [19, 20]. We designated this  
61 variant 501Y.V2.HVdF002. HV represents the outgrowth protocol which included initial outgrowth in  
62 a human H1299 cell line derivative overexpressing the ACE2 receptor, followed by a cell-to-cell infection  
63 of Vero E6 cells (Materials and methods). dF represents the deletion of the furin cleavage site. Deletion  
64 of the furin cleavage site may not affect neutralization [19]. However, we proceeded to test an additional  
65 501Y.V2 variant. This variant, which we designated 501Y.V2.HV001, had an additional mutation, L18F,  
66 in the NTD prior to outgrowth and showed no changes in spike sequence after outgrowth.

67 We mixed the virus with serially diluted participant plasma, then added the mixture to Vero E6  
68 cells and counted infection foci after 28 hours (Figure 2A, Materials and methods). There was a clear  
69 visual difference in the number of foci as a function of plasma dilution. 501Y.V2.HV001 also showed  
70 dramatically larger foci (Figure 2A).

71 We normalized the number of foci to the number of foci in the absence of plasma on the same plate  
72 to obtain the transmission index (Tx, [21]). In this context, it is the number of foci in the presence of  
73 plasma inhibition divided by the number of foci in the absence of plasma. This controls for experiment  
74 variability between plates and experiments. The data from the FFA approximated a normal distribution  
75 (Figure S1) and we therefore used parametric statistics to describe it. We observed neutralization of the  
76 first wave virus which varied between plasma samples (Figure 2B). To obtain the  $IC_{50}$ , we fitted the data  
77 for each participant to a sigmoidal function [22] with  $IC_{50}$  as the only free parameter (Materials and  
78 methods). Fitted  $IC_{50}$  values (Figure 2D) varied between  $4 \times 10^{-3}$  for participant 039-13-0013 to  $1 \times 10^{-4}$   
79 for participants 039-13-0033 and 039-02-0015, consistent with the previously observed heterogeneity in  
80 neutralization between individuals [16, 17].

81 We next determined neutralization of 501Y.V2. A decline in plasma neutralization was clearly ob-  
82 served (Figure 2A). T501Y.V2.HV001 also showed attenuated neutralization likely greater than that  
83 of 501Y.V2.HVdF002 (Figure S2), ruling out the *in vitro* generated deletion in the furin cleavage site  
84 as being responsible for escape. We combined the data for both 501Y.V2 variants. Fitted  $IC_{50}$  values  
85 varied between  $1 \times 10^{-3}$  (1:100 dilution) for plasma from participant 039-13-0033 to a complete knock-  
86 out of activity for plasma from participant 039-13-0013 (Figure 2D). The 501Y.V2 to first wave  $IC_{50}$   
87 ratio ranged from 6 to 200-fold (Figure 2D). Averaging across all participants highlighted the dramatic  
88 decrease in sensitivity to neutralization of authentic 501Y.V2 variants (Figure 2E).



**Figure 2: Neutralization of first wave and 501Y.V2 variants by convalescent plasma from first wave infections.** (A) A representative focus forming assay using plasma from participant 039-13-0015. Plasma neutralization of (B) first wave virus and (C) the combined results from the two 501Y.V2 variants. Colored circles represent means and standard errors from 8 independent neutralization experiments using plasma from 6 convalescent participants who were infected by first wave variants in the first peak of the pandemic in South Africa. Correspondingly colored lines are fits of the sigmoidal equation with  $IC_{50}$  as the fitted parameter. Black points represent a pool of plasma from three uninfected controls. The transmission index (Tx) is the number of foci in the presence of the plasma dilution normalized by the number of foci in the absence of plasma. (D) Plasma  $IC_{50}$  values and ratios for first wave and 501Y.V2 variants. Knockout (KO) was scored as  $IC_{50} > 1$ . ND, not defined. (E) Mean and standard error across all plasma donors.

89 As we have entered the second year of the SARS-CoV-2 pandemic with high levels of transmission in  
90 many parts of the world, variants with mutations at key residues in the spike glycoprotein have emerged.  
91 Here we present clear evidence using authentic SARS-CoV-2 that the 501Y.V2 variant first detected  
92 in South Africa is associated with reduced neutralization by plasma collected from patients infected  
93 in the first wave with SARS-CoV-2 variants without the 501Y.V2 defining RBD and NTD mutations.  
94 While our findings are based on plasma samples from six convalescent study participants, the relative  
95 consistency of the effect argues that the potential to escape neutralizing antibodies elicited by prior  
96 SARS-CoV-2 infection may be widespread.

97 The reduced neutralization is most likely related to the mutations in the spike RBD and NTD that  
98 characterize the 501Y.V2 variant. While the E484K mutation has the clearest association with immune  
99 escape, the other mutations in the RBD (K417N, N501Y) are also located within residues targeted  
100 by some class 1 and class 2 NAbs [7]. Information about the significance of NTD mutations is also  
101 emerging. NAbs targeting this site have been shown to be potent neutralizers of SARS-CoV-2 [5, 6].  
102 The deletion at residues 242-244 is just outside an antigenic supersite loop (residues 245-264) and L18  
103 also falls within the antigenic supersite. Furthermore, mutations at L18 and D80 have been selected  
104 during passage with mAbs [5]. Our second variant contains the L18F mutation. This may be associated  
105 with the trend to lower neutralization sensitivity relative to the first 501Y.V2 variant (Figure S2). This  
106 variant also has strikingly larger foci (Figure 2A).

107 The reasons for the rapid emergence and fixation of potential immune escape mutations in South  
108 Africa remain unclear. The 501Y.V2 variant was first detected in the Eastern Cape Province of South  
109 Africa, in Nelson Mandela Bay, an urban municipality with a population of just over one million.  
110 While we have no SARS-CoV-2 seroprevalence data from this area, there were 1909 excess natural  
111 deaths (approximately 1600 per million population) by the end of the first wave in mid-September (  
112 <https://www.samrc.ac.za/reports/report-weekly-deaths-south-africa>). In the context of a young popu-  
113 lation (over 80 percent of the population under 50 years), this data would suggest a high attack rate  
114 from the first wave. While circumstantial, this provides some support to a hypothesis of high levels of  
115 population immunity driving the selection of variants with capacity to evade natural immunity. This  
116 area also has high HIV prevalence, and has amongst the lowest proportions of people with HIV who have  
117 viral suppression (<http://www.hivdata.org.za/>). We have not observed evidence of chronic SARS-CoV-2  
118 infection in people living with HIV in our longitudinal cohort [15]. However, most cohort participants  
119 had sustained virological suppression with antiretroviral therapy (ART). We did observe altered im-  
120 mune dynamics after SARS-CoV-2 infection in HIV viremic participants relative to those who were  
121 virologically suppressed, and we are currently enrolling additional participants to examine SARS-CoV-2  
122 clearance in the HIV viremic subset.

123 The implications of these results for re-infection and vaccine efficacy are still unclear. Our findings  
124 emphasize the need to understand whether the 501Y.V2 variant, and other similar variants, are associ-  
125 ated with an increased rate of re-infection. Vaccines such as the Oxford/Astra Zeneca ChAdOx1 [23]  
126 and the Pfizer-BioNTech BNT162b2 [24] elicit neutralization titers in a similar range to the convalescent  
127 plasma in this study. However, these vaccines may elicit a broader antibody response and protective T  
128 cell immunity [25]. Protective T cell immunity also likely occurs following natural infection. Further-  
129 more, it is unclear what degree of neutralization mediates protection, and infection may be particularly  
130 sensitive to inhibition at exposure [26].

131 In conclusion, we present data suggesting that the 501Y.V2 variant first detected in South Africa  
132 is able to escape the neutralizing antibody response elicited by natural infection with earlier variants.  
133 We expect data in the next weeks from phase 3 vaccine trials being conducted in South Africa. If the  
134 variant does have an effect on vaccine efficacy, then there may be a signal in the data from these clinical  
135 trials.

## 136 **Material and methods**

### 137 **Ethical statement**

138 Nasopharyngeal/oropharyngeal swab samples and plasma samples were obtained from six hospital-  
139 ized adults with PCR-confirmed SARS-CoV-2 infection enrolled in a prospective cohort study ap-  
140 proved by the Biomedical Research Ethics Committee (BREC) at the University of KwaZulu-Natal  
141 (reference BREC/00001275/2020). The 501Y.V2 variants were obtained from residual nasopharyn-  
142 geal/oropharyngeal samples used for routine SARS-CoV-2 diagnostic testing by the National Health  
143 Laboratory Service, through our SARS-CoV-2 genomic surveillance program (BREC approval reference  
144 BREC/00001510/2020).

### 145 **Whole genome sequencing, genome assembly and phylogenetic analysis**

146 cDNA synthesis was performed on the extracted RNA using random primers followed by gene specific  
147 multiplex PCR using the ARTIC V3 protocol. Briefly, extracted RNA was converted to cDNA using the  
148 Superscript IV First Strand synthesis system (Life Technologies, Carlsbad, CA) and random hexamer  
149 primers. SARS-CoV-2 whole genome amplification was performed by multiplex PCR using primers de-  
150 signed on Primal Scheme (<http://primal.zibraproject.org/>) to generate 400bp amplicons with an overlap  
151 of 70bp that covers the 30Kb SARS-CoV-2 genome. PCR products were cleaned up using AmpureXP  
152 purification beads (Beckman Coulter, High Wycombe, UK) and quantified using the Qubit dsDNA  
153 High Sensitivity assay on the Qubit 4.0 instrument (Life Technologies Carlsbad, CA). We then used the  
154 Illumina® Nextera Flex DNA Library Prep kit according to the manufacturer's protocol to prepare  
155 indexed paired end libraries of genomic DNA. Sequencing libraries were normalized to 4nM, pooled and  
156 denatured with 0.2N sodium acetate. 12pM sample library was spiked with 1% PhiX (PhiX Control v3  
157 adapter-ligated library used as a control). We sequenced libraries on a 500-cycle v2 MiSeq Reagent Kit  
158 on the Illumina MiSeq instrument (Illumina, San Diego, CA). We have previously published full details  
159 of the amplification and sequencing protocol [27].

160 We assembled paired-end fastq reads using Genome Detective 1.126 (<https://www.genomedetective.com>)  
161 and the Coronavirus Typing Tool [28]. We polished the initial assembly obtained from Genome Detective  
162 by aligning mapped reads to the references and filtering out low-quality mutations using bcftools 1.7-2  
163 mpileup method. Mutations were confirmed visually with bam files using Geneious software (Biomatters  
164 Ltd, Auckland, New Zealand). All of the sequences were deposited in GISAID (<https://www.gisaid.org/>).  
165 We retrieved all South African SARS-CoV-2 genotypes from the GISAID database as of 11 January  
166 2021 (N=2704). We initially analyzed South African genotypes against the global reference dataset  
167 (N=2592) using a custom pipeline based on a local version of NextStrain. The pipeline contains several  
168 python scripts that manage the analysis workflow. It performs alignment of genotypes in MAFFT [29],  
169 phylogenetic tree inference in IQ-Tree20, tree dating and ancestral state construction and annotation  
170 (<https://github.com/nextstrain/ncov>).

### 171 **Cells**

172 Vero E6 cells (ATCC CRL-1586, obtained from Cellonex) were propagated in complete DMEM with 10%  
173 fetal bovine serum (Hylone) containing 1% each of HEPES, sodium pyruvate, L-glutamine, and non-  
174 essential amino acids (Sigma-Aldrich). Cells were passaged every 3-4 days. H1299 cells were propagated  
175 in complete RPMI with 10% fetal bovine serum containing 1% each of HEPES, sodium pyruvate, L-  
176 glutamine, and non-essential amino acids and and passaged every second day.

### 177 **H1299-E3 cell line for first passage SARS-CoV-2 outgrowth**

178 The H1299-H2AZ clone with nuclear labelled YFP [30] was constructed to overexpress ACE2 as follows:  
179 VSVG-pseudotyped lentivirus containing the human ACE2 was generated by co-transfecting 293T cells  
180 with the pHAGE2-EF1aInt-ACE2-WT plasmid along with the lentiviral helper plasmids HDM-VSVG,

181 HDM-Hgpm2, HDM-tat1b and pRC-CMV-Rev1b using TransIT-LT1 (Mirus) transfection reagent. Su-  
182 pernatant containing the lentivirus was harvested two days after infection, filtered through a  $0.45\mu\text{m}$   
183 filter (Corning) and used to spinfect H1299-H2AZ at 1000 rcf for 2 hours at room temperature in the pres-  
184 ence of  $5\mu\text{g}/\text{mL}$  polybrene (Sigma-Aldrich). ACE-2 transduced H1299-H2AZ cells were then subcloned  
185 at the single cell density in 96-well plates (Eppendorf) in conditioned media derived from confluent cells.  
186 After 3 weeks, wells were trypsinized (Sigma-Aldrich) and plated in two replicate plates, where the first  
187 plate was used to determine infectivity and the second was stock. The first plate was screened for the  
188 fraction of mCherry positive cells per cell clone upon infection with SARS-CoV-2 mCherry expressing  
189 Spike pseudotyped lentiviral vector 1610-pHAGE2/EF1a Int-mCherry3-W produced by transfecting as  
190 above. Screening was performed using a Metamorph-controlled (Molecular Devices, Sunnyvale, CA)  
191 Nikon TiE motorized microscope (Nikon Corporation, Tokyo, Japan) with a 20x, 0.75 NA phase ob-  
192 jective, 561 laser line, and 607 nm emission filter (Semrock, Rochester, NY). Images were captured  
193 using an 888 EMCCD camera (Andor). Temperature ( $37^\circ\text{C}$ ), humidity and  $\text{CO}_2$  (5%) were controlled  
194 using an environmental chamber (OKO Labs, Naples, Italy). The clone with the highest fraction of  
195 mCherry expression was expanded from the stock plate and denoted H1299-E3. This clone was used in  
196 the outgrowth.

## 197 **Viral Outgrowth**

198 All live virus work was performed in Biosafety level 3 containment using AHRI Institutional Biosafety  
199 Committee approved protocols for SARS-CoV-2. For first wave virus, a T25 flask (Corning) was seeded  
200 with Vero E6 cells at  $2 \times 10^5$  cells/ml and incubated for 18-20 hours. After 1 DPBS wash, the sub-  
201 confluent cell monolayer was inoculated with  $500\mu\text{L}$  universal transport medium (UTM) diluted 1:1  
202 with growth medium and filtered through a  $0.45\mu\text{M}$  filter. Cells were incubated for 1 hour. Flask was  
203 then filled with 7mL of complete growth medium and checked daily for cytopathic effect (CPE). Four  
204 days post infection, supernatants of the infected culture were collected, centrifuged at 300 rcf for 3  
205 minutes to remove cell debris, and filtered using a  $0.45\mu\text{M}$  filter. Viral supernatant was aliquoted and  
206 stored at  $-80^\circ\text{C}$ . For 501Y.V2 variants, we used H1299-ACE2-E3 cells for initial isolation followed by  
207 passage into Vero E6 cells. H1299-ACE2-E3 cells were seeded at  $1.5 \times 10^5$  cells/ml and incubated for  
208 18-20 hours. After 1 DPBS wash, the sub-confluent cell monolayer was inoculated with  $500\mu\text{L}$  universal  
209 transport medium (UTM) diluted 1:1 with growth medium and filtered through a  $0.45\mu\text{M}$  filter. Cells  
210 were incubated for 1 hour. Wells were then filled with 3mL of complete growth medium. 8 days post-  
211 infection, cells were trypsinized, centrifuged at 300 rcf for 3 minutes and resuspended in 4mL growth  
212 medium. 1mL was added to Vero E6 cells that had been seeded at  $t 2 \times 10^5$  cells/ml 18-20 hours earlier  
213 in a T25 flask (approximately 1:8 donor-to-target cell dilution ratio) for cell-to-cell infection. Coculture  
214 of H1299-ACE2-E3 and Vero E6 cells was incubated for 1 hour and flask was then filled with 7mL of  
215 complete growth medium and incubated for 6 days. Viral supernatant was aliquoted and stored at  
216  $-80^\circ\text{C}$  or further passaged in Vero E6 cells as above.

## 217 **Microneutralization using focus forming assay**

218 Vero E6 cells were plated in an 96 well plate (Eppendorf) at 30,000 cells per well 1 day pre-infection.  
219 Plasma was separated from EDTA-anticoagulated blood by centrifugation at 500 rcf for 10 minutes and  
220 stored at  $-80^\circ\text{C}$ . Aliquots of plasma samples were heat-inactivated at  $56^\circ\text{C}$  for 30 minutes, and clarified  
221 by centrifugation at 10,000 rcf for 5 minutes, where the clear middle layer was used for experiments.  
222 Inactivated plasma was stored in single use aliquots to prevent freeze-thaw cycles. For experiments,  
223 plasma was serially diluted two-fold from 1:100 to 1:1600. Virus stocks were used at approximately 50  
224 focus-forming units (FFU) per microwell and added to diluted plasma; antibody-virus mixtures were  
225 incubated for 1 hour at  $37^\circ\text{C}$ , 5%  $\text{CO}_2$ . Cells were infected with  $100\mu\text{L}$  of the virus-antibody mixtures,  
226 to allow adsorption of virus. Subsequently,  $100\mu\text{L}$  of a 1x RPMI 1640 (Sigma-Aldrich R6504), 1.5%  
227 carboxymethylcellulose (Sigma-Aldrich C4888) overlay was added to the wells without removing the  
228 inoculum. Cells were fixed at 28 hours post-infection using 4% paraformaldehyde (Sigma-Aldrich) for  
229 20 minutes. For staining of foci, a rabbit anti-Spike monoclonal antibody (mAb BS-R2B12, GenScript



230 A02058) was used at 0.5 $\mu$ g/mL as the primary detection antibody. Antibody was resuspended in  
231 a permeabilization buffer containing 0.1% saponin (Sigma-Aldrich), 0.1% BSA (Sigma-Aldrich), and  
232 0.05% tween (Sigma-Aldrich) in PBS. Plates were incubated with primary antibody overnight at 4°C,  
233 then washed with wash buffer containing 0.05% tween in PBS. Secondary goat anti-rabbit horseradish  
234 peroxidase (Abcam ab205718) was added at 1  $\mu$ g/mL and incubated for 2 hours at room temperature  
235 with shaking. The TrueBlue peroxidase substrate (SeraCare 5510-0030) was then added at 50 $\mu$ L per  
236 well and incubated for 20 minutes at room temperature. Plates were then dried for 2 hours and imaged  
237 using a Metamorph-controlled Nikon TiE motorized microscope with a 2x objective. Automated image  
238 analysis was performed using a Matlab2019b (Mathworks) custom script, where focus detection was  
239 automated and did not involve user curation. Image segmentation steps were stretching the image from  
240 minimum to maximum intensity, local Laplacian filtering, image complementation, thresholding and  
241 binarization. For the second 501Y.V2 variant, a dilation/erosion step was introduced to prevent the  
242 large foci from fragmenting into smaller objects.

## 243 **Statistics and fitting**

244 All statistics and fitting were performed using Matlab2019b. Neutralization data was fit to

$$Tx = 1/1 + (D/IC_{50}).$$

245 Here Tx is the number of foci normalized to the number of foci in the absence of plasma on the same  
246 plate at dilution D. Fit to a normal distribution using Matlab2019b function normplot, which compared  
247 the distribution of the Tx data to the normal distribution (see <https://www.mathworks.com/help/stats/normplot.html>).

## 248 **Acknowledgements**

249 This work was supported by the Bill and Melinda Gates Investment INV-018944 (AS) and by the South  
250 African Medical Research Council and the Department of Science and Innovation (TDO).

## 251 **§ Network for Genomic Surveillance in South Africa (NGS-SA)**

252 Shareef Abrahams<sup>1</sup>, Luiz Carlos Junior Alcantara<sup>2</sup>, Arghavan Alisoltani-Dehkordi<sup>3,4</sup>, Mushal Allam<sup>5</sup>,  
253 Jinal N Bhiman<sup>5,6</sup>, Mary-Ann Davies<sup>7,8</sup>, Deelan Doolabh<sup>9</sup>, Susan Engelbrecht<sup>10</sup>, Vagner Fonseca<sup>11</sup>,  
254 Marta Giovanetti<sup>2</sup>, Allison J Glass<sup>6,12</sup>, Adam Godzik<sup>4</sup>, Dominique Goedhals<sup>13</sup>, Diana Hardie<sup>14</sup>, Mar-  
255 vin Hsiao<sup>14</sup>, Arash Iranzadeh<sup>4</sup>, Arshad Ismail<sup>5</sup>, Stephen Korsman<sup>14</sup>, Sergei L Kosakovsky Pond<sup>15</sup>,  
256 Oluwakemi Laguda-Akingba<sup>1,16</sup>, Jose Lourenco<sup>17</sup>, Gert Marais<sup>14</sup>, Darren Martin<sup>9,18</sup>, Caroline Maslo<sup>19</sup>,  
257 Koleka Mlisana<sup>20,21</sup>, Thabo Mohale<sup>5</sup>, Nokukhanya Msomi<sup>22</sup>, Innocent Mudau<sup>9</sup>, Francesco Petruccione<sup>23,24</sup>,  
258 Wolfgang Preiser<sup>10</sup>, Emmanuel James San<sup>11</sup>, Bryan Trevor Sewell<sup>25</sup>, Lynn Tyers<sup>9</sup>, Gert Van Zyl<sup>10</sup>,  
259 Anne von Gottberg<sup>5,6</sup>, Sibongile Walaza<sup>5,26</sup>, Steven Weaver<sup>15</sup>, Constantinos Kurt Wibmer<sup>5</sup>, Carolyn  
260 Williamson<sup>9,14,21</sup>, Denis York<sup>27</sup>.

261 <sup>1</sup>National Health Laboratory Service, Port Elizabeth, South Africa. <sup>2</sup>Laboratorio de Flavivirus, Fun-  
262 dacao Oswaldo Cruz, Rio de Janeiro, Brazil. <sup>3</sup>Division of Medical Virology, Department of Pathology,  
263 University of Cape Town, Cape Town, South Africa. <sup>4</sup>Division of Biomedical Sciences, University of  
264 California Riverside School of Medicine, Riverside, California, USA. <sup>5</sup>National Institute for Commu-  
265 nicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa. <sup>6</sup>School of  
266 Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.  
267 <sup>7</sup>Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South  
268 Africa. <sup>8</sup>Western Cape Government: Health, Cape Town, South Africa. <sup>9</sup>Division of Medical Virology,  
269 Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South  
270 Africa. <sup>10</sup>Division of Medical Virology at NHLS Tygerberg Hospital and Faculty of Medicine and Health  
271 Sciences, Stellenbosch University, Cape Town, South Africa. <sup>11</sup>KwaZulu-Natal Research Innovation and

272 Sequencing Platform (KRISP), Department of Laboratory Medicine and Medical Sciences, University  
273 of KwaZulu-Natal, Durban, South Africa. <sup>12</sup>Department of Molecular Pathology, Lancet Laboratories,  
274 Johannesburg, South Africa. <sup>13</sup>Division of Virology at NHLS Universitas Academic Laboratories, Uni-  
275 versity of The Free State, Bloemfontein, South Africa. <sup>14</sup>Division of Medical Virology at NHLS Groote  
276 Schuur Hospital, University of Cape Town, Cape Town, South Africa. <sup>15</sup>Institute for Genomics and  
277 Evolutionary Medicine, Temple University, Philadelphia, Pennsylvania, USA. <sup>16</sup>Department of Labo-  
278 ratory Medicine and Pathology, Faculty of Health Sciences, Walter Sisulu University, Mthatha, South  
279 Africa. <sup>17</sup>Department of Zoology, University of Oxford, Oxford, United Kingdom. <sup>18</sup>Computational Bi-  
280 ology Division, Department of Integrative Biomedical Sciences, University of Cape Town, Cape Town,  
281 South Africa. <sup>19</sup>Department of Quality Leadership, Netcare Hospitals, Johannesburg, South Africa.  
282 <sup>20</sup>National Health Laboratory Service, Johannesburg, South Africa. <sup>21</sup>Centre for the AIDS Programme  
283 of Research in South Africa (CAPRISA), Durban, South Africa. <sup>22</sup>Discipline of Virology, University of  
284 KwaZulu-Natal, School of Laboratory Medicine and Medical Sciences and National Health Laboratory  
285 Service, Durban, South Africa. <sup>23</sup>Centre for Quantum Technology, University of KwaZulu-Natal, Dur-  
286 ban, South Africa <sup>24</sup>National Institute for Theoretical Physics (NITheP), KwaZulu-Natal, South Africa.  
287 <sup>25</sup>Structural Biology Research Unit, Department of Integrative Biomedical Sciences, University of Cape  
288 Town, Rondebosch, South Africa. <sup>26</sup>School of Public Health, Faculty of Health Sciences, University  
289 of the Witwatersrand, Johannesburg, South Africa. <sup>27</sup>Molecular Diagnostics Services, Durban, South  
290 Africa.

## 291 § § COMMIT-KZN Team

292 Moherndran Archary<sup>1</sup>, Kaylesh J. Dullabh<sup>2</sup>, Philip Goulder<sup>3,4</sup>, Guy Harling<sup>3,5</sup>, Rohen Harrichandparsad<sup>6</sup>,  
293 Kobus Herbst<sup>3,7</sup>, Prakash Jeena<sup>1</sup>, Thandeka Khoza<sup>3</sup>, Nigel Klein<sup>3,8</sup>, Henrik Kløverpris<sup>3,9,10</sup>, Alasdair  
294 Leslie<sup>3,9</sup>, Rajhmun Madansein<sup>2</sup>, Mohlopheni Marakalala<sup>3,9</sup>, Matilda Mazibuko<sup>3</sup>, Mosa Moshabela<sup>11</sup>,  
295 Ntombifuthi Mthabela<sup>3</sup>, Kogie Naidoo<sup>12</sup>, Zaza Ndhlovu<sup>3,13</sup>, Thumbi Ndung'u<sup>3,9,14,15</sup>, Kennedy Nyamande<sup>16</sup>,  
296 Nesri Padayatchi<sup>12</sup>, Vinod Patel<sup>17</sup>, Theresa Smit<sup>3</sup>, Adrie Steyn<sup>3,18</sup>, Emily Wong<sup>3,18</sup>.

297 <sup>1</sup>Department of Paediatrics and Child Health, University of KwaZulu-Natal, Durban, South Africa.  
298 <sup>2</sup>Department of Cardiothoracic Surgery, University of KwaZulu-Natal, Durban, South Africa. <sup>3</sup>Africa  
299 Health Research Institute, Durban, South Africa. <sup>4</sup>Department of Paediatrics, Oxford, UK. <sup>5</sup>Institute  
300 for Global Health, University College London, UK. <sup>6</sup>Department of Neurosurgery, University of KwaZulu-  
301 Natal, Durban, South Africa. <sup>7</sup>South African Population Research Infrastructure Network, Durban,  
302 South Africa. <sup>8</sup>Institute of Child Health, University College London, UK. <sup>9</sup>Division of Infection and  
303 Immunity, University College London, London, UK. <sup>10</sup>Department of Immunology and Microbiology,  
304 University of Copenhagen, Copenhagen, Denmark. <sup>11</sup>College of Health Sciences, University of KwaZulu-  
305 Natal, Durban, South Africa. <sup>12</sup>Centre for the AIDS Programme of Research in South Africa, Durban,  
306 South Africa. <sup>13</sup>Ragon Institute of MGH, MIT and Harvard, Boston, USA. <sup>14</sup>HIV Pathogenesis Pro-  
307 gramme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South  
308 Africa. <sup>15</sup>Max Planck Institute for Infection Biology, Berlin, Germany. <sup>16</sup>Department of Pulmonology  
309 and Critical Care, University of KwaZulu-Natal, Durban, South Africa. <sup>17</sup>Department of Neurology,  
310 University of KwaZulu-Natal, Durban, South Africa. <sup>18</sup>Division of Infectious Diseases, University of  
311 Alabama at Birmingham.

## 312 References

313 [1] Houriiyah Tegally, Eduan Wilkinson, Marta Giovanetti, Arash Iranzadeh, Vagner Fonseca,  
314 Jennifer Giandhari, Deelan Doolabh, Sureshnee Pillay, Emmanuel James San, Nokukhanya  
315 Msomi, Koleka Mlisana, Anne von Gottberg, Sibongile Walaza, Mushal Allam, Arshad Ismail,  
316 Thabo Mohale, Allison J Glass, Susan Engelbrecht, Gert Van Zyl, Wolfgang Preiser, Francesco  
317 Petruccione, Alex Sigal, Diana Hardie, Gert Marais, Marvin Hsiao, Stephen Korsman, Mary-

- 318 Ann Davies, Lynn Tyers, Innocent Mudau, Denis York, Caroline Maslo, Dominique Goedhals,  
319 Shareef Abrahams, Oluwakemi Laguda-Akingba, Arghavan Alisoltani-Dehkordi, Adam Godzik,  
320 Constantinos Kurt Wibmer, Bryan Trevor Sewell, José Lourenço, Luiz Carlos Junior Alcantara,  
321 Sergei L Kosakovsky Pond, Steven Weaver, Darren Martin, Richard J Lessells, Jinal N Bhiman,  
322 Carolyn Williamson, and Tulio de Oliveira. Emergence and rapid spread of a new severe acute  
323 respiratory syndrome-related coronavirus 2 (sars-cov-2) lineage with multiple spike mutations in  
324 south africa. *medRxiv*, page 2020.12.21.20248640, 2020. doi: 10.1101/2020.12.21.20248640. URL  
325 <https://www.medrxiv.org/content/medrxiv/early/2020/12/22/2020.12.21.20248640.full.pdf>.
- [2] Erik Volz, Swapnil Mishra, Meera Chand, Jeffrey C. Barrett, Robert Johnson, Lily Geidel-  
326 berg, Wes R Hinsley, Daniel J Laydon, Gavin Dabrera, Áine O’Toole, Roberto Amato, Manon  
327 Ragonnet-Cronin, Ian Harrison, Ben Jackson, Cristina V. Ariani, Olivia Boyd, Nick Loman, John T  
328 McCrone, Sónia Gonçalves, David Jorgensen, Richard Myers, Verity Hill, David K. Jackson, Katy  
329 Gaythorpe, Natalie Groves, John Sillitoe, Dominic P. Kwiatkowski, Seth Flaxman, Oliver  
330 Ratmann, Samir Bhatt, Susan Hopkins, Axel Gandy, Andrew Rambaut, and Neil M Ferguson.  
331 Transmission of sars-cov-2 lineage b.1.1.7 in england: Insights from linking epidemiological and  
332 genetic data. *medRxiv*, page 2020.12.30.20249034, 2021. doi: 10.1101/2020.12.30.20249034. URL  
333 <https://www.medrxiv.org/content/medrxiv/early/2021/01/04/2020.12.30.20249034.full.pdf>.
- [3] Carolina M Voloch, Ronaldo da Silva F, Luiz G P de Almeida, Cynthia C Cardoso, Otavio J.  
335 Brustolini, Alexandra L Gerber, Ana Paula de C Guimarães, Diana Mariani, Raissa Mirella da  
336 Costa, Orlando C. Ferreira, Adriana Cony Cavalcanti, Thiago Silva Frauches, Claudia Maria Braga  
337 de Mello, Rafael Mello Galliez, Débora Souza Faffe, Terezinha M P P Castiñeiras, Amilcar Tanuri,  
338 and Ana Tereza R de Vasconcelos. Genomic characterization of a novel sars-cov-2 lineage from rio de  
339 janeiro, brazil. *medRxiv*, page 2020.12.23.20248598, 2020. doi: 10.1101/2020.12.23.20248598. URL  
340 <https://www.medrxiv.org/content/medrxiv/early/2020/12/26/2020.12.23.20248598.full.pdf>.
- [4] L. Piccoli, Y. J. Park, M. A. Tortorici, N. Czudnochowski, A. C. Walls, M. Beltramello, C. Silacci-  
342 Fregni, D. Pinto, L. E. Rosen, J. E. Bowen, O. J. Acton, S. Jaconi, B. Guarino, A. Minola, F. Zatta,  
343 N. Sprugasci, J. Bassi, A. Peter, A. De Marco, J. C. Nix, F. Mele, S. Jovic, B. F. Rodriguez,  
344 S. V. Gupta, F. Jin, G. Piumatti, G. Lo Presti, A. F. Pellanda, M. Biggiogero, M. Tarkowski,  
345 M. S. Pizzuto, E. Cameroni, C. Havenar-Daughton, M. Smithey, D. Hong, V. Lepori, E. Albanese,  
346 A. Ceschi, E. Bernasconi, L. Elzi, P. Ferrari, C. Garzoni, A. Riva, G. Snell, F. Sallusto, K. Fink,  
347 H. W. Virgin, A. Lanzavecchia, D. Corti, and D. Velesler. Mapping neutralizing and immunodom-  
348 inant sites on the sars-cov-2 spike receptor-binding domain by structure-guided high-resolution  
349 serology. *Cell*, 183(4):1024–1042 e21, 2020. ISSN 1097-4172 (Electronic) 0092-8674 (Linking). doi:  
350 10.1016/j.cell.2020.09.037. URL <https://www.ncbi.nlm.nih.gov/pubmed/32991844>.
- [5] Matthew McCallum, Anna De Marco, Florian Lempp, M. Alejandra Tortorici, Dora Pinto,  
352 Alexandra C. Walls, Martina Beltramello, Alex Chen, Zhuoming Liu, Fabrizia Zatta, Samantha  
353 Zepeda, Julia di Iulio, John E. Bowen, Martin Montiel-Ruiz, Jiayi Zhou, Laura E. Rosen, Siro  
354 Bianchi, Barbara Guarino, Chiara Silacci Fregni, Rana Abdelnabi, Shi-Yan Caroline Foo, Paul W.  
355 Rothlauf, Louis-Marie Bloyet, Fabio Benigni, Elisabetta Cameroni, Johan Neyts, Agostino Riva,  
356 Gyorgy Snell, Amalio Telenti, Sean P.J. Whelan, Herbert W. Virgin, Davide Corti, Matteo Samuele  
357 Pizzuto, and David Velesler. N-terminal domain antigenic mapping reveals a site of vulnerability  
358 for sars-cov-2. *bioRxiv*, page 2021.01.14.426475, 2021. doi: 10.1101/2021.01.14.426475. URL  
359 <https://www.biorxiv.org/content/biorxiv/early/2021/01/14/2021.01.14.426475.full.pdf>.
- [6] Gabriele Cerutti, Yicheng Guo, Tongqing Zhou, Jason Gorman, Myungjin Lee, Micah Rapp,  
361 Eswar R. Reddem, Jian Yu, Fabiana Bahna, Jude Bimela, Yaoxing Huang, Phinikoula S.  
362 Katsamba, Lihong Liu, Manoj S. Nair, Reda Rawi, Adam S. Olia, Pengfei Wang, Gwo-Yu  
363 Chuang, David D. Ho, Zizhang Sheng, Peter D. Kwong, and Lawrence Shapiro. Potent  
364 sars-cov-2 neutralizing antibodies directed against spike n-terminal target a single  
365 supersite. *bioRxiv*, page 2021.01.10.426120, 2021. doi: 10.1101/2021.01.10.426120. URL  
366 <https://www.biorxiv.org/content/biorxiv/early/2021/01/11/2021.01.10.426120.full.pdf>.
- 367

- 368 [7] C. O. Barnes, C. A. Jette, M. E. Abernathy, K. A. Dam, S. R. Esswein, H. B. Gristick, A. G.  
369 Malyutin, N. G. Sharaf, K. E. Huey-Tubman, Y. E. Lee, D. F. Robbiani, M. C. Nussenzweig, Jr.  
370 West, A. P., and P. J. Bjorkman. Sars-cov-2 neutralizing antibody structures inform therapeutic  
371 strategies. *Nature*, 588(7839):682–687, 2020. ISSN 1476-4687 (Electronic) 0028-0836 (Linking). doi:  
372 10.1038/s41586-020-2852-1. URL <https://www.ncbi.nlm.nih.gov/pubmed/33045718>.
- 373 [8] Alina Baum, Benjamin O Fulton, Elzbieta Wloga, Richard Copin, Kristen E Pascal, Vincenzo  
374 Russo, Stephanie Giordano, Kathryn Lanza, Nicole Negron, and Min Ni. Antibody cocktail to  
375 sars-cov-2 spike protein prevents rapid mutational escape seen with individual antibodies. *Science*,  
376 369(6506):1014–1018, 2020. ISSN 0036-8075.
- 377 [9] A. J. Greaney, T. N. Starr, P. Gilchuk, S. J. Zost, E. Binshtein, A. N. Loes, S. K. Hilton, J. Hud-  
378 dleston, R. Eguia, K. H. D. Crawford, A. S. Dingens, R. S. Nargi, R. E. Sutton, N. Suryadevara,  
379 P. W. Rothlauf, Z. Liu, S. P. J. Whelan, R. H. Carnahan, Jr. Crowe, J. E., and J. D. Bloom.  
380 Complete mapping of mutations to the sars-cov-2 spike receptor-binding domain that escape anti-  
381 body recognition. *Cell Host Microbe*, 2020. ISSN 1934-6069 (Electronic) 1931-3128 (Linking). doi:  
382 10.1016/j.chom.2020.11.007. URL <https://www.ncbi.nlm.nih.gov/pubmed/33259788>.
- 383 [10] Z. Liu, H. Zheng, H. Lin, M. Li, R. Yuan, J. Peng, Q. Xiong, J. Sun, B. Li, J. Wu, L. Yi,  
384 X. Peng, H. Zhang, W. Zhang, R. J. G. Hulswit, N. Loman, A. Rambaut, C. Ke, T. A. Bowden,  
385 O. G. Pybus, and J. Lu. Identification of common deletions in the spike protein of severe acute  
386 respiratory syndrome coronavirus 2. *J Virol*, 94(17), 2020. ISSN 1098-5514 (Electronic) 0022-538X  
387 (Linking). doi: 10.1128/JVI.00790-20. URL <https://www.ncbi.nlm.nih.gov/pubmed/32571797>.
- 388 [11] Y. Weisblum, F. Schmidt, F. Zhang, J. DaSilva, D. Poston, J. C. Lorenzi, F. Muecksch,  
389 M. Rutkowska, H. H. Hoffmann, E. Michailidis, C. Gaebler, M. Agudelo, A. Cho, Z. Wang,  
390 A. Gazumyan, M. Cipolla, L. Luchsinger, C. D. Hillyer, M. Caskey, D. F. Robbiani, C. M. Rice,  
391 M. C. Nussenzweig, T. Hatziioannou, and P. D. Bieniasz. Escape from neutralizing antibodies by  
392 sars-cov-2 spike protein variants. *Elife*, 9, 2020. ISSN 2050-084X (Electronic) 2050-084X (Linking).  
393 doi: 10.7554/eLife.61312. URL <https://www.ncbi.nlm.nih.gov/pubmed/33112236>.
- 394 [12] E. Andreano, G. Piccini, D. Licastro, L. Casalino, N. V. Johnson, I. Paciello, S. D. Monego,  
395 E. Pantano, N. Manganaro, A. Manenti, R. Manna, E. Casa, I. Hyseni, L. Benincasa, E. Mon-  
396 tomoli, R. E. Amaro, J. S. McLellan, and R. Rappuoli. Sars-cov-2 escape in vitro from a highly  
397 neutralizing covid-19 convalescent plasma. *bioRxiv*, 2020. doi: 10.1101/2020.12.28.424451. URL  
398 <https://www.ncbi.nlm.nih.gov/pubmed/33398278>.
- 399 [13] Zhuoming Liu, Laura A. VanBlargan, Louis-Marie Bloyet, Paul W. Rothlauf, Rita E.  
400 Chen, Spencer Stumpf, Haiyan Zhao, John M. Errico, Elitza S. Theel, Mariel J. Liebe-  
401 skind, Brynn Alford, William J. Buchser, Ali H. Ellebedy, Daved H. Fremont, Michael S.  
402 Diamond, and Sean P. J. Whelan. Landscape analysis of escape variants identifies  
403 sars-cov-2 spike mutations that attenuate monoclonal and serum antibody neutraliza-  
404 tion. *bioRxiv*, page 2020.11.06.372037, 2021. doi: 10.1101/2020.11.06.372037. URL  
405 <https://www.biorxiv.org/content/biorxiv/early/2021/01/11/2020.11.06.372037.full.pdf>.
- 406 [14] Allison J Greaney, Andrea N Loes, Katharine HD Crawford, Tyler N Starr, Keara D Malone, He-  
407 len Y Chu, and Jesse D Bloom. Comprehensive mapping of mutations to the sars-cov-2 receptor-  
408 binding domain that affect recognition by polyclonal human serum antibodies. *bioRxiv*, page  
409 2020.12. 31.425021, 2021.
- 410 [15] Farina Karim, Inbal Gazy, Sandile Cele, Yenzekile Zungu, Robert Krause, Mallory  
411 Bernstein, Yashica Ganga, Hylton Rodel, Ntombifuthi Mthabela, Matilda Mazibuko,  
412 Khadija Khan, Daniel Muema, Dirhona Ramjit, Gila Lustig, Thumbi Ndung’u, Willem  
413 Hanekom, Bernadett I. Gosnell, Emily Wong, Tulio de Oliveira, Mahomed-Yunus S.  
414 Moosa, Alasdair Leslie, Henrik Kløverpris, and Alex Sigal. Hiv infection alters sars-  
415 cov-2 responsive immune parameters but not clinical outcomes in covid-19 disease.

416 *medRxiv*, page 2020.11.23.20236828, 2020. doi: 10.1101/2020.11.23.20236828. URL  
417 <https://www.medrxiv.org/content/medrxiv/early/2020/11/24/2020.11.23.20236828.full.pdf>.

418 [16] D. F. Robbiani, C. Gaebler, F. Muecksch, J. C. C. Lorenzi, Z. Wang, A. Cho, M. Agudelo, C. O.  
419 Barnes, A. Gazumyan, S. Finkin, T. Hagglof, T. Y. Oliveira, C. Viant, A. Hurley, H. H. Hoffmann,  
420 K. G. Millard, R. G. Kost, M. Cipolla, K. Gordon, F. Bianchini, S. T. Chen, V. Ramos, R. Patel,  
421 J. Dizon, I. Shimeliovich, P. Mendoza, H. Hartweiger, L. Nogueira, M. Pack, J. Horowitz, F. Schmidt,  
422 Y. Weisblum, E. Michailidis, A. W. Ashbrook, E. Waltari, J. E. Pak, K. E. Huey-Tubman, N. Ko-  
423 randa, P. R. Hoffman, Jr. West, A. P., C. M. Rice, T. Hatzioannou, P. J. Bjorkman, P. D. Bieniasz,  
424 M. Caskey, and M. C. Nussenzweig. Convergent antibody responses to sars-cov-2 in convalescent  
425 individuals. *Nature*, 584(7821):437–442, 2020. ISSN 1476-4687 (Electronic) 0028-0836 (Linking).  
426 doi: 10.1038/s41586-020-2456-9. URL <https://www.ncbi.nlm.nih.gov/pubmed/32555388>.

427 [17] C. Gaebler, Z. Wang, J. C. C. Lorenzi, F. Muecksch, S. Finkin, M. Tokuyama, A. Cho, M. Jankovic,  
428 D. Schaefer-Babajew, T. Y. Oliveira, M. Cipolla, C. Viant, C. O. Barnes, Y. Bram, G. Breton,  
429 T. Hagglof, P. Mendoza, A. Hurley, M. Turroja, K. Gordon, K. G. Millard, V. Ramos, F. Schmidt,  
430 Y. Weisblum, D. Jha, M. Tankelevich, G. Martinez-Delgado, J. Yee, R. Patel, J. Dizon, C. Unson-  
431 O’Brien, I. Shimeliovich, D. F. Robbiani, Z. Zhao, A. Gazumyan, R. E. Schwartz, T. Hatzioannou,  
432 P. J. Bjorkman, S. Mehandru, P. D. Bieniasz, M. Caskey, and M. C. Nussenzweig. Evolution of  
433 antibody immunity to sars-cov-2, 2021. ISSN 1476-4687 (Electronic) 0028-0836 (Linking). URL  
434 <https://www.ncbi.nlm.nih.gov/pubmed/33461210>.

435 [18] James Brett Case, Adam L Bailey, Arthur S Kim, Rita E Chen, and Michael S Diamond. Growth,  
436 detection, quantification, and inactivation of sars-cov-2. *Virology*, 2020.

437 [19] W. B. Klimstra, N. L. Tilston-Lunel, S. Nambulli, J. Boslett, C. M. McMillen, T. Gilliland, M. D.  
438 Dunn, C. Sun, S. E. Wheeler, A. Wells, A. L. Hartman, A. K. McElroy, D. S. Reed, L. J. Ren-  
439 nick, and W. P. Duprex. Sars-cov-2 growth, furin-cleavage-site adaptation and neutralization  
440 using serum from acutely infected hospitalized covid-19 patients. *J Gen Virol*, 101(11):1156–  
441 1169, 2020. ISSN 1465-2099 (Electronic) 0022-1317 (Linking). doi: 10.1099/jgv.0.001481. URL  
442 <https://www.ncbi.nlm.nih.gov/pubmed/32821033>.


443 [20] A. C. Walls, Y. J. Park, M. A. Tortorici, A. Wall, A. T. McGuire, and D. Velesler. Struc-  
444 ture, function, and antigenicity of the sars-cov-2 spike glycoprotein. *Cell*, 181(2):281–292 e6,  
445 2020. ISSN 1097-4172 (Electronic) 0092-8674 (Linking). doi: 10.1016/j.cell.2020.02.058. URL  
446 <https://www.ncbi.nlm.nih.gov/pubmed/32155444>.

447 [21] A. Sigal, J. T. Kim, A. B. Balazs, E. Dekel, A. Mayo, R. Milo, and D. Baltimore. Cell-to-  
448 cell spread of hiv permits ongoing replication despite antiretroviral therapy. *Nature*, 477(7362):  
449 95–8, 2011. ISSN 1476-4687 (Electronic) 0028-0836 (Linking). doi: 10.1038/nature10347. URL  
450 <https://www.ncbi.nlm.nih.gov/pubmed/21849975>.


451 [22] L. Shen, S. Peterson, A. R. Sedaghat, M. A. McMahon, M. Callender, H. Zhang, Y. Zhou,  
452 E. Pitt, K. S. Anderson, E. P. Acosta, and R. F. Siliciano. Dose-response curve slope  
453 sets class-specific limits on inhibitory potential of anti-hiv drugs. *Nat Med*, 14(7):762–  
454 6, 2008. ISSN 1546-170X (Electronic) 1078-8956 (Linking). doi: 10.1038/nm1777. URL  
455 <https://www.ncbi.nlm.nih.gov/pubmed/18552857>.

456 [23] M. N. Ramasamy, A. M. Minassian, K. J. Ewer, A. L. Flaxman, P. M. Folegatti, D. R. Owens,  
457 M. Voysey, P. K. Aley, B. Angus, G. Babbage, S. Belij-Rammerstorfer, L. Berry, S. Bibi, M. Bit-  
458 taye, K. Cathie, H. Chappell, S. Charlton, P. Cicconi, E. A. Clutterbuck, R. Colin-Jones, C. Dold,  
459 K. R. W. Emary, S. Fedosyuk, M. Fuskova, D. Gbesemete, C. Green, B. Hallis, M. M. Hou,  
460 D. Jenkin, C. C. D. Joe, E. J. Kelly, S. Kerridge, A. M. Lawrie, A. Lelliott, M. N. Lwin,  
461 R. Makinson, N. G. Marchevsky, Y. Mujadidi, A. P. S. Mumro, M. Pacurar, E. Plested, J. Rand,  
462 T. Rawlinson, S. Rhead, H. Robinson, A. J. Ritchie, A. L. Ross-Russell, S. Saich, N. Singh,

- 463 C. C. Smith, M. D. Snape, R. Song, R. Tarrant, Y. Themistocleous, K. M. Thomas, T. L. Vil-  
464 lafana, S. C. Warren, M. E. E. Watson, A. D. Douglas, A. V. S. Hill, T. Lambe, S. C. Gilbert,  
465 S. N. Faust, A. J. Pollard, and Covid Vaccine Trial Group Oxford. Safety and immunogenic-  
466 ity of chadox1 ncov-19 vaccine administered in a prime-boost regimen in young and old adults  
467 (cov002): a single-blind, randomised, controlled, phase 2/3 trial. *Lancet*, 396(10267):1979–1993,  
468 2021. ISSN 1474-547X (Electronic) 0140-6736 (Linking). doi: 10.1016/S0140-6736(20)32466-1.  
469 URL <https://www.ncbi.nlm.nih.gov/pubmed/33220855>.
- 470 [24] E. E. Walsh, Jr. Frenck, R. W., A. R. Falsey, N. Kitchin, J. Absalon, A. Gurtman, S. Lock-  
471 hart, K. Neuzil, M. J. Mulligan, R. Bailey, K. A. Swanson, P. Li, K. Koury, W. Kalina,  
472 D. Cooper, C. Fontes-Garfias, P. Y. Shi, O. Tureci, K. R. Tompkins, K. E. Lyke, V. Raabe,  
473 P. R. Dormitzer, K. U. Jansen, U. Sahin, and W. C. Gruber. Safety and immunogenic-  
474 ity of two rna-based covid-19 vaccine candidates. *N Engl J Med*, 383(25):2439–2450, 2020.  
475 ISSN 1533-4406 (Electronic) 0028-4793 (Linking). doi: 10.1056/NEJMoa2027906. URL  
476 <https://www.ncbi.nlm.nih.gov/pubmed/33053279>.
- 477 [25] Alba Grifoni, Daniela Weiskopf, Sydney I Ramirez, Jose Mateus, Jennifer M Dan, Carolyn Ry-  
478 dzyński Moderbacher, Stephen A Rawlings, Aaron Sutherland, Lakshmanane Premkumar, and  
479 Ramesh S Jadi. Targets of t cell responses to sars-cov-2 coronavirus in humans with covid-19  
480 disease and unexposed individuals. *Cell*, 2020. ISSN 0092-8674.
- 481 [26] A. Moyano, G. Lustig, H. E. Rodel, T. Antal, and A. Sigal. Interference with hiv infection of  
482 the first cell is essential for viral clearance at sub-optimal levels of drug inhibition. *PLoS Comput*  
483 *Biol*, 16(2):e1007482, 2020. ISSN 1553-7358 (Electronic) 1553-734X (Linking). doi: 10.1371/jour-  
484 nal.pcbi.1007482. URL <https://www.ncbi.nlm.nih.gov/pubmed/32017770>.
- 485 [27] Sureshnee Pillay, Jennifer Giandhari, Houriiyah Tegally, Eduan Wilkinson, Benjamin Chimukan-  
486 gara, Richard Lessells, Stacey Mattison, Yunus Moosa, Inbal Gazy, Maryam Fish, et al. Whole  
487 genome sequencing of sars-cov-2: Adapting illumina protocols for quick and accurate outbreak  
488 investigation during a pandemic. *bioRxiv*, 2020.
- 489 [28] Sara Cleemput, Wim Dumon, Vagner Fonseca, Wasim Abdool Karim, Marta Giovanetti, Luiz Car-  
490 los Alcantara, Koen Deforche, and Tulio De Oliveira. Genome detective coronavirus typing tool  
491 for rapid identification and characterization of novel coronavirus genomes. *Bioinformatics*, 36(11):  
492 3552–3555, 2020.
- 493 [29] Kazutaka Katoh, Kazuharu Misawa, Kei-ichi Kuma, and Takashi Miyata. Mafft: a novel method  
494 for rapid multiple sequence alignment based on fast fourier transform. *Nucleic acids research*, 30  
495 (14):3059–3066, 2002.
- 496 [30] A. Sigal, R. Milo, A. Cohen, N. Geva-Zatorsky, Y. Klein, I. Alaluf, N. Swerdlin, N. Perzov,  
497 T. Danon, Y. Liron, T. Raveh, A. E. Carpenter, G. Lahav, and U. Alon. Dynamic proteomics  
498 in individual human cells uncovers widespread cell-cycle dependence of nuclear proteins. *Nat Meth-*  
499 *ods*, 3(7):525–31, 2006. ISSN 1548-7091 (Print) 1548-7091 (Linking). doi: 10.1038/nmeth892. URL  
500 <https://www.ncbi.nlm.nih.gov/pubmed/16791210>.



**Figure S 1: Fit of combined data for each plasma dilution to a normal distribution.** The Matlab2019b function normplot was used to assess the fit of the data (blue crosses) to a normal distribution (solid red line). Lack of pronounced curvature of the data in the range of the solid line indicates that the data is a reasonably good fit to a normal distribution. see <https://www.mathworks.com/help/stats/normplot.html> for additional information.



**Figure S 2: Neutralization of first wave and 501Y.V2 by convalescent plasma from first wave infections separated by variant.** Four sets of independent experiments were performed per 501Y.V2 - first wave pair, where the matched first wave variant results are shown to the left of the 501Y.V2 neutralization results. 501Y.V2 variant 2 contained the L18F mutation in addition to the mutations of variant 1, and did not have the furin cleavage site deletion from outgrowth in Vero E6 cells. Colored points represent means and standard errors from 4 independent experiments for each 501Y.V2 variant/first wave pair of neutralization activity of plasma from 6 convalescent participants infected by first wave viruses. Corresponding lines are fits of the sigmoidal equation with  $IC_{50}$  as the fitted parameter. Black points represent a pool of plasma from three uninfected controls. The transmission index (Tx) is the number of foci in the presence of the plasma dilution normalized by the number of foci in the absence of plasma.



Table S 1: Plasma donor characteristics

PID	Sex	Disease severity	Days between symptom onset and swab	Days between symptom onset and plasma	Spike mutations
039-02-0014	F	Mild	13	27	D614G
039-02-0017	F	Supp. O <sub>2</sub>	7	28	D614G
039-13-0013	F	Mild	3	30	D614G, A688V
039-13-0015	F	Mild	12	26	D614G
039-13-0033	F	Mild	23	30	D614G
039-13-0062	M	Mild	12	26	D614G

**Table S 2: Mutation profile for the genomes of the outgrown viruses and for the infecting viruses of convalescent plasma donors**

Lineage	Outgrown virus			Infecting virus from plasma donors					
	B.1.1	B.1.351 (S10Y.V2)	B.1.351 (S01Y.V2)	B.1.1	B.1.1	B.1.5	B.1.5	B.1.140	B.1.1.1
Sequence ID	K002868	K005321	K005325	K002868	K004289	K004285	K004291	K004295	K004302
Accession ID	EPI_ISL_602622	EPI_ISL_678570	EPI_ISL_678615	EPI_ISL_602622	EPI_ISL_660170	EPI_ISL_660167	EPI_ISL_660172	EPI_ISL_660167	EPI_ISL_660181
Cohort ID	039-13-0013	-	-	039-13-0013	039-02-0014	039-13-0015	039-13-0033	039-02-0017	039-13-0062
Spike amino acid substitutions	S:D614G S:A688V	S:D80A S:D215G S:K417N S:E484K S:N501Y S:D614G S:A701V	S:L18F S:D80A S:D215G S:K417N S:E484K S:N501Y S:D614G S:A701V	S:D614G S:A688V	S:D614G	S:D614G	S:D614G	S:D614G	S:D614G
Spike deletions		S:242-244del	S:242-244del						
Other amino acid substitutions	N:L139F N:R203K N:G204R ORF14:G50N ORF1a:D148IN ORF1b:P314L	E:P71L N:T205I ORF14:L52F ORF1a:T265I ORF1a:K1655N ORF1a:K3353R ORF1b:P314L ORF3a:Q57H ORF3a:S171L ORF7a:V93F	E:P71L N:T205I ORF14:L52F ORF1a:T265I ORF1a:K1655N ORF1a:K3353R ORF1b:P314L ORF3a:Q57H ORF3a:S171L ORF7a:V93F	N:L139F N:R203K N:G204R ORF14:G50N ORF1a:D148IN ORF1b:P314L	E:L73P N:R203K N:G204R ORF14:G50N ORF1a:D148IN ORF1b:P314L	E:L73P ORF1a:D3728N ORF1b:P314L	N:T148A ORF10:A28V ORF1a:K2511R ORF1a:V3858I ORF1b:P314L	ORF1a:F1178S ORF1b:P314L	N:R203K N:G204R ORF14:G50N ORF1a:T1246I ORF1a:G3278S ORF1b:P314L
Other deletions		orf1ab:3675-3677del	orf1ab:3675-3677del						

Lineage classification was performed by Pangolin software application version v2.1.7 (<https://cov-lineages.org/pangolin.html>).

Accession ID refers to GISAID EpiCoV™ database ([www.gisaid.org](http://www.gisaid.org))

Amino acid mutation nomenclature includes open reading frame, wild-type amino acid, ORF position and amino-acid mutation (e.g. S:D80A, Spike D to A substitution at position 80). del refers to deletion between stated positions. Amino acid mutations are annotated based on mature protein region of coding sequence (CDS) of SARS-CoV-2 reference sequence NC\_045512.2.

Table S 3: Mutation profile for the genomes of the outgrown 501Y.V2 viruses, showing the original genome produced from the nasopharyngeal swab specimen and the genomes generated following passage in VeroE6 cells

Sequence ID	Outgrown 501Y.V2 Original	Outgrown 501Y.V2 After passage 2	Outgrown 501Y.V2 After passage 3	Outgrown 501Y.V2 Original	Outgrown 501Y.V2 After passage 3
Spike amino acid substitutions	K005321 S:D80A S:D215G S:K417N S:E484K S:N501Y S:D614G S:A701V	K007776 S:D80A S:D215G S:K417N S:E484K S:N501Y S:D614G S:A701V	K007624 S:D80A S:D215G S:K417N S:E484K S:N501Y S:D614G S:A701V	K005325 S:L18F S:D80A S:D215G S:K417N S:E484K S:N501Y S:D614G S:A701V	K007621 S:L18F S:D80A S:D215G S:K417N S:E484K S:N501Y S:D614G S:A701V
Spike deletions	S:242-244del	S:242-244del <b>S:677-681del</b>	S:242-244del <b>S:677-681del</b>	S:242-244del	S:242-244del
Other amino acid substitutions	E:P71L N:T205I ORF14:L52F ORF1a:T265I ORF1a:K1655N ORF1a:K3353R ORF1b:P314L ORF3a:Q57H ORF3a:S171L	E:P71L N:T205I ORF14:L52F ORF1a:T265I ORF1a:K1655N ORF1a:K3353R <b>ORF1a:Q3878R</b> ORF1b:P314L ORF3a:Q57H ORF3a:S171L	E:P71L N:T205I ORF14:L52F ORF1a:T265I ORF1a:K1655N ORF1a:K3353R <b>ORF1a:Q3878R</b> ORF1b:P314L ORF3a:Q57H ORF3a:S171L	E:P71L N:T205I ORF14:L52F ORF1a:T265I ORF1a:K1655N ORF1b:P314L ORF3a:Q57H ORF3a:W131L ORF7a:V93F	E:P71L N: <b>R32H</b> N:T205I ORF14:L52F ORF1a:T265I ORF1a:K1655N ORF1b:P314L <b>ORF1a:N4358K</b> ORF1b:P314L ORF3a:Q57H ORF3a:W131L ORF3a:S171L ORF7a:V93F <b>ORF9b:A29T</b>
Other deletions	orf1ab:3675-3677del	orf1ab:3675-3677del	orf1ab:3675-3677del	orf1ab:3675-3677del	orf1ab:3675-3677del

Amino acid mutation nomenclature includes open reading frame, wild-type amino acid, ORF position and amino-acid mutation (e.g. S:D80A, Spike D to A substitution at position 80). del refers to deletion between stated positions. Amino acid mutations are annotated based on mature protein region of coding sequence (CDS) of SARS-CoV-2 reference sequence NC\_045512.2. Substitutions and deletions in bold are those emerging during passage